Belenos Biosciences develops long‑acting bispecific antibody therapeutics that simultaneously target upstream alarmins (such as TSLP or OX40L) and downstream cytokines (IL‑13) to achieve broader, more durable suppression of type 2 inflammation. Their platform enables a single injection to provide sustained pathway coverage across multiple chronic inflammatory diseases—including asthma, COPD, atopic dermatitis, and chronic rhinosinusitis—aiming for consistent clinical remission with reduced dosing frequency.
Funding
$48M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for chronic inflammatory diseases such as asthma, COPD, atopic dermatitis, and chronic rhinosinusitis often target a single cytokine pathway, resulting in incomplete disease control and limited rates of clinical remission.
Solution
Belenos Biosciences develops long‑acting bispecific antibody therapeutics that simultaneously modulate upstream epithelial alarmins and downstream effector cytokines implicated in type 2 inflammation. By combining targets such as TSLP with IL‑13 (BEL512) or OX40L with IL‑13 (BEL536) in a single molecule, the platform aims to achieve broader and more durable suppression of inflammatory cascades than monotherapy. The bispecific design enables a single injection to provide sustained pathway coverage, reducing dosing frequency and improving patient adherence. Clinical programs are advancing these candidates across multiple indications characterized by epithelial‑immune dysregulation, with the goal of delivering consistent, lasting remission for patients.
Target Audience
Primary users are pulmonologists, allergists, dermatologists, and other clinicians treating chronic type 2 inflammatory diseases, as well as healthcare systems seeking therapies that deliver durable remission with reduced dosing burden.
Features
- Bispecific antibody architecture that co‑targets an upstream alarmin (TSLP or OX40L) and a downstream effector (IL‑13) within one long‑acting molecule
- Engineered Fc region for extended half‑life, supporting infrequent dosing schedules
- Dual mechanism of action designed to block both initiation and maintenance phases of type 2 inflammatory responses
- Clinical development programs spanning asthma, COPD, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, atopic dermatitis, food allergy, and scleroderma
- Proprietary platform enabling rapid generation of additional bispecific candidates for diverse inflammatory pathways
- Preclinical and early clinical data indicating superior cytokine suppression and tissue remodeling outcomes compared with single‑target antibodies